Because the current drug label for Depo-Provera Contraceptive Injection (version “Revised: 7/2024”, accessed 10/16/24) does not include any warning about an increased risk of intracranial meningioma, we are investigating possible Depo-Provera meningioma brain tumors drug injury lawsuits seeking … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens … More
No Federal Preemption for Fosamax MDL Femur Fracture Lawsuits: September 2024 Update
The United States Court of Appeals for the Third Circuit recently issued this opinion, In re: Fosamax (alendronate sodium) Products Liability Litigation, No. 22-3412, (3d Cir. Sept. 20, 2024), ruling that there is no federal preemption for more than 500 Fosamax MDL femur fracture lawsuits that had … More
FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda … More
Menopause Drug Veozah Liver Problems FDA Warnings
A Veozah drug label change made on August 31, 2024, added new warnings about liver toxicity and abnormal liver test results, according to a September 12, 2024, Veozah liver problems FDA Drug Safety Communication. According to the “Additional Information for Patients” section of the September 2024 … More
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Abstract: The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in … More